Evidence map›Paper›PMID 25922183›Full record

ArticleBioorganic & medicinal chemistry2015

Chimeric derivatives of functionalized amino acids and α-aminoamides: compounds with anticonvulsant activity in seizure models and inhibitory actions on central, peripheral, and cardiac isoforms of voltage-gated sodium channels.

Robert Torregrosa, Xiao-Fang Yang, Erik T Dustrude, Theodore R Cummins, Rajesh Khanna, Harold Kohn

Open access · bronzeAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Robert TorregrosaNeuroGate Therapeutics, Inc., 150 Fayetteville Street, Suite 2300, Raleigh, NC 27601, United States.
Xiao-Fang YangDepartment of Pharmacology and Neuroscience Graduate Interdisciplinary Program, College of Medicine, University of Arizona, Tucson, AZ 85742, United States.
Erik T DustrudeProgram in Medical Neuroscience, Paul and Carole Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, United States.
Theodore R CumminsProgram in Medical Neuroscience, Paul and Carole Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, United States; Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, United States.
Rajesh KhannaDepartment of Pharmacology and Neuroscience Graduate Interdisciplinary Program, College of Medicine, University of Arizona, Tucson, AZ 85742, United States.
Harold KohnNeuroGate Therapeutics, Inc., 150 Fayetteville Street, Suite 2300, Raleigh, NC 27601, United States; Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, United States; Department of Chemistry, University of North Carolina, Chapel Hill, NC 27599, United States.
Indiana University School of MedicineUniversity of Arizona · USUniversity of North Carolina at Chapel Hill · US

Funding

Sodium channels and electrogenesis in sensory neuronsR01NS053422 · NINDS · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI CUMMINS, THEODORE R · 2006 to 2019
$4.6M
Sodium channels and electrogenesis in sensory neuronsR56NS053422 · NINDS · INDIANA UNIVERSITY INDIANAPOLIS · PI CUMMINS, THEODORE R · 2015 to 2015
$390k
Extended NeuroAmides: Novel Antiepileptic Drug CandidatesR41NS080278 · NINDS · NEUROGATE THERAPEUTICS, INC. · PI KOHN, HAROLD · 2012 to 2012
$249k
NINDS NIH HHS 1 R41 NS080278NINDS NIH HHS NS053422NINDS NIH HHS R01 NS053422NINDS NIH HHS R41 NS080278NINDS NIH HHS R56 NS053422
6 · The paper itself

Abstract

Six novel 3″-substituted (R)-N-(phenoxybenzyl) 2-N-acetamido-3-methoxypropionamides were prepared and then assessed using whole-cell, patch-clamp electrophysiology for their anticonvulsant activities in animal seizure models and for their sodium channel activities. We found compounds with various substituents at the terminal aromatic ring that had excellent anticonvulsant activity. Of these compounds, (R)-N-4'-((3″-chloro)phenoxy)benzyl 2-N-acetamido-3-methoxypropionamide ((R)-5) and (R)-N-4'-((3″-trifluoromethoxy)phenoxy)benzyl 2-N-acetamido-3-methoxypropionamide ((R)-9) exhibited high protective indices (PI=TD50/ED50) comparable with many antiseizure drugs when tested in the maximal electroshock seizure test to mice (intraperitoneally) and rats (intraperitoneally, orally). Most compounds potently transitioned sodium channels to the slow-inactivated state when evaluated in rat embryonic cortical neurons. Treating HEK293 recombinant cells that expressed hNaV1.1, rNaV1.3, hNaV1.5, or hNaV1.7 with (R)-9 recapitulated the high levels of sodium channel slow inactivation.

Indexed as

AcetamidesAdministration, OralAmidesAmino AcidsAnimalsAnticonvulsantsCerebral CortexElectroshockHEK293 CellsHumansInjections, IntraperitonealMaleMiceNeuronsPatch-Clamp TechniquesPrimary Cell CultureAcetamidesAmidesAmino AcidsAnticonvulsantsN-4'-((3'-trifluoromethoxy)phenoxy)benzyl 2-N-acetamido-3-methoxypropionamideVoltage-Gated Sodium Channel BlockersVoltage-Gated Sodium ChannelsAntiseizure agentsChimeric agentsFunctionalized amino acidsNa(+) current inhibitionα-Aminoamides

Identifiers

PMID25922183
PMCPMC4461516
OpenAlexW2006135366

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.